Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Toby Trahair

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 21, 2021
Randomized Trial of Two Induction Therapy Regimens for High-Risk Neuroblastoma: HR-NBL1.5 International Society of Pediatric Oncology European Neuroblastoma Group StudyAlberto Garaventa, Ulrike Poetschger, Dominique Valteau-Couanet, et al.
The Lancet. Haematology|September 24, 2021
Minimal residual disease, long-term outcome, and IKZF1 deletions in children and adolescents with Down syndrome and acute lymphocytic leukaemia: a matched cohort studyNaomi Michels, Judith M Boer, Amir Enshaei, et al.
Cancer Biology & Therapy|October 10, 2018
Integration of genomics, high throughput drug screening, and personalized xenograft models as a novel precision medicine paradigm for high risk pediatric cancerMaria Tsoli, Carol Wadham, Mark Pinese, et al.
The Lancet. Oncology|November 17, 2018
Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trialRuth Ladenstein, Ulrike Pötschger, Dominique Valteau-Couanet, et al.
Cancers|February 5, 2020
Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)Ruth Ladenstein, Ulrike Pötschger, Dominique Valteau-Couanet, et al.
Hemasphere|January 26, 2026
Blinatumomab in de novo AYA ALL-Results of the Australasian Leukaemia and Lymphoma Group ALL09 "SUBLIME" studyMatthew Greenwood, Shane Gangatharan, Michael Osborn, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|March 19, 2025
The Super Enhancer-Driven Long Noncoding RNA PRKCQ-AS1 Promotes Neuroblastoma Tumorigenesis by Interacting With MSI2 Protein and Is Targetable by Small Molecule CompoundsSujanna Mondal, Pei Y Liu, Janith Seneviratne, et al.
The Lancet. Oncology|March 6, 2017
Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trialRuth Ladenstein, Ulrike Pötschger, Andrew D J Pearson, et al.
NPJ Genomic Medicine|February 17, 2025
Returning raw genomic data to research participants in a pediatric cancer precision medicine trialKristine Barlow-Stewart, Eliza Courtney, Mark Cowley, et al.
Cancer Research|October 17, 2015
WDR5 Supports an N-Myc Transcriptional Complex That Drives a Protumorigenic Gene Expression Signature in NeuroblastomaYuting Sun, Jessica L Bell, Daniel Carter, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 21, 2021
Randomized Trial of Two Induction Therapy Regimens for High-Risk Neuroblastoma: HR-NBL1.5 International Society of Pediatric Oncology European Neuroblastoma Group StudyAlberto Garaventa, Ulrike Poetschger, Dominique Valteau-Couanet, et al.
The Lancet. Haematology|September 24, 2021
Minimal residual disease, long-term outcome, and IKZF1 deletions in children and adolescents with Down syndrome and acute lymphocytic leukaemia: a matched cohort studyNaomi Michels, Judith M Boer, Amir Enshaei, et al.
Cancer Biology & Therapy|October 10, 2018
Integration of genomics, high throughput drug screening, and personalized xenograft models as a novel precision medicine paradigm for high risk pediatric cancerMaria Tsoli, Carol Wadham, Mark Pinese, et al.
The Lancet. Oncology|November 17, 2018
Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trialRuth Ladenstein, Ulrike Pötschger, Dominique Valteau-Couanet, et al.
Cancers|February 5, 2020
Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)Ruth Ladenstein, Ulrike Pötschger, Dominique Valteau-Couanet, et al.
Hemasphere|January 26, 2026
Blinatumomab in de novo AYA ALL-Results of the Australasian Leukaemia and Lymphoma Group ALL09 "SUBLIME" studyMatthew Greenwood, Shane Gangatharan, Michael Osborn, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|March 19, 2025
The Super Enhancer-Driven Long Noncoding RNA PRKCQ-AS1 Promotes Neuroblastoma Tumorigenesis by Interacting With MSI2 Protein and Is Targetable by Small Molecule CompoundsSujanna Mondal, Pei Y Liu, Janith Seneviratne, et al.
The Lancet. Oncology|March 6, 2017
Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trialRuth Ladenstein, Ulrike Pötschger, Andrew D J Pearson, et al.
NPJ Genomic Medicine|February 17, 2025
Returning raw genomic data to research participants in a pediatric cancer precision medicine trialKristine Barlow-Stewart, Eliza Courtney, Mark Cowley, et al.
Cancer Research|October 17, 2015
WDR5 Supports an N-Myc Transcriptional Complex That Drives a Protumorigenic Gene Expression Signature in NeuroblastomaYuting Sun, Jessica L Bell, Daniel Carter, et al.
Pageof 4